Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totalling 114,100 shares, a growth of 14.3% from the June 30th total of 99,800 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average daily volume of 450,300 shares, the short-interest ratio is currently 0.3 days.
Analyst Ratings Changes
Separately, LADENBURG THALM/SH SH downgraded Coeptis Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 18th.
Read Our Latest Analysis on COEP
Coeptis Therapeutics Trading Down 2.0 %
Coeptis Therapeutics (NASDAQ:COEP – Get Free Report) last announced its earnings results on Friday, May 10th. The company reported ($0.08) earnings per share (EPS) for the quarter. Sell-side analysts expect that Coeptis Therapeutics will post -0.26 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Coeptis Therapeutics stock. Armistice Capital LLC grew its position in shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Free Report) by 59.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,520,000 shares of the company’s stock after purchasing an additional 1,308,000 shares during the period. Armistice Capital LLC owned about 10.32% of Coeptis Therapeutics worth $2,759,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.88% of the company’s stock.
Coeptis Therapeutics Company Profile
Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.
Read More
- Five stocks we like better than Coeptis Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Survey: Top 175 Fittest Retirement Locations in America
- How to Start Investing in Real Estate
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What is a Stock Market Index and How Do You Use Them?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.